Literature DB >> 20975304

Underfinancing of 90.3% for implant costs of prostheses and expanders in DRG revenues for uni- and bilateral mastectomy with immediate breast reconstruction.

Volker R Jacobs1, Linda Rasche, Nadia Harbeck, Mathias Warm, Peter Mallmann.   

Abstract

BACKGROUND: From the clinic's point of view economic patient care requires comparison and adjustment of costs to revenues. To verify cost coverage for implants in mastectomy with immediate breast reconstruction, a comprehensive cost-reimbursement analysis was performed.
METHODS: Retrospective analysis of the German diagnosis-related group (G-DRG) revenues for implants from the DRG Browser 2007/2009HA and comparison with actual costs for implants in 2009 from the annual clinic report and the database of the controlling department. Calculation of the relative cost coverage for implants in unilateral (DRG J06Z) and bilateral mastectomy (DRG J16Z).
RESULTS: In 2009, n = 98 J06Z and n = 18 J16Z were performed. DRG-calculated expenses for implants were € 69.65 for J06Z and € 123.07 for J16Z, i.e. a total of € 9,040.96. Actual costs for all implants were € 121,645.60, mean € 699.11 (€ 404.94-1,171.44). Attributable implant costs for 100% immediate breast reconstruction rate were € 93,679.28. Thus, implants are not cost covering by -90.3% (-82.8 to -94.7%). Subsidies for implants from the clinic's budget range from € 335.29 to € 2,219.81 per case.
CONCLUSIONS: Immediate breast reconstruction with implants after mastectomy is - even 6 years after introduction of the DRGs - not adequately calculated to be cost covering since the actual implant costs exceed the calculated revenues by far. At present, these implants are subsidized by the clinic at, on average, 90.3%. If economic patient care is mandatory, a maximum of only 1 in 10 patients with mastectomy can be offered immediate breast reconstruction with implants in Germany.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20975304     DOI: 10.1159/000321144

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  7 in total

1.  Influence of Patient and Hospital Characteristics on the Performance of Direct Reconstruction after Mastectomy.

Authors:  J Hartrampf; L Ansmann; S Wesselmann; M W Beckmann; H Pfaff; C Kowalski
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-12       Impact factor: 2.915

Review 2.  Relevance of health economics in breast cancer treatment: integration of economics in the management of breast cancer at the clinic level.

Authors:  Volker R Jacobs; Gerhard Bogner; Christiane E Schausberger; Roland Reitsamer; Thorsten Fischer
Journal:  Breast Care (Basel)       Date:  2013-03       Impact factor: 2.860

Review 3.  Relevance of health economics in breast cancer treatment - the view of certified breast centres and their patients.

Authors:  Michael Lux; Thomas Hildebrandt; Elke Beyer-Finkler; Mayada Bani; Christian Loehberg; Sebastian Jud; Claudia Rauh; Michael Schrauder; Peter Fasching; Matthias Beckmann
Journal:  Breast Care (Basel)       Date:  2013-03       Impact factor: 2.860

4.  Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ.

Authors:  Catherine A Richards; Andrew G Rundle; Jason D Wright; Dawn L Hershman
Journal:  JAMA Surg       Date:  2018-04-01       Impact factor: 14.766

Review 5.  Breast cancer surgery and financial reimbursement in Germany.

Authors:  Juergen Hoffmann; Diethelm Wallwiener
Journal:  Breast Care (Basel)       Date:  2012-10       Impact factor: 2.860

6.  Characteristics and related factors of emergency department visits, readmission, and hospital transfers of inpatients under a DRG-based payment system: A nationwide cohort study.

Authors:  Pei-Fang Huang; Pei-Tseng Kung; Wen-Yu Chou; Wen-Chen Tsai
Journal:  PLoS One       Date:  2020-12-09       Impact factor: 3.240

Review 7.  A pragmatic guide on how physicians can take over financial control of their clinical practice.

Authors:  Volker R Jacobs; Thorsten Fischer
Journal:  JSLS       Date:  2012 Oct-Dec       Impact factor: 2.172

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.